Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

• Published in: Journal of headache and pain Vol. 21; no. 1; pp. 62 - 9
• Main Authors: Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar Muhsen, Eigenbrodt, Anna Kristina, Larsen, Eigil Lindekilde, Andersen, Amalie Middelboe, Hansen, Kevin John, Bräuner, Karoline Bendix, Mørch-Jessen, Thomas, Chaudhry, Basit, Antic, Sonja, Christensen, Casper Emil, Ashina, Messoud, Amin, Faisal Mohammad, Schytz, Henrik Winther
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 03.06.2020; Springer Nature B.V; BMC
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Brain Concussion - complications; Brain Concussion - diagnosis; Brain Concussion - drug therapy; Calcitonin; Calcitonin gene-related peptide; Calcitonin Gene-Related Peptide Receptor Antagonists - adverse effects; Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use; Clinical management; Clinical trials; Concussion; Constipation; Double-Blind Method; Female; Follow-Up Studies; Head injury; Head trauma; Headache; Headaches; Humans; Injections, Subcutaneous; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Neurology; Pain Medicine; Parathyroid hormone; Patients; Post-Traumatic Headache - diagnosis; Post-Traumatic Headache - drug therapy; Post-Traumatic Headache - etiology; Research Article; Safety; Secondary headache; Traumatic brain injury; Treatment Outcome; Young Adult; Secondary headache; Clinical management; Head trauma; Concussion; Head injury
• ISSN: 1129-2369; 1129-2377; 1129-2377
• DOI: 10.1186/s10194-020-01136-z

Background Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and...